Biostem Technologies Inc

OTC:BSEM

BioStem Technologies, Inc. engages in the provision of regenerative medicine and anti-aging solutions. The company is headquartered in Pompano Beach, Florida. The company went IPO on 2001-07-11. The firm is focused on harnessing elements of perinatal tissue and the body’s innate biology to repair or reverse damage caused by a range of degenerative diseases. Its approach, called Local MicroEnvironment Activation (LMA) platform uses combinations of small molecules, cytokines, and growth factors to activate the microenvironment within the body to create communication for repair in the tissue. Its products include RHEO, OROPRO, AEON, VENDAJE, VENDAJE AC, VENDAJE OPTIC, PROVISCUS, NEOFYL and ONIX. Its RHEO is a cushioning agent for homologous supplementation, which is derived from human amniotic tissue. Its OROPRO is derived from human umbilical cord and is a Wharton's jelly tissue allograft. Its VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. The VENDAJE AC is a structural tissue allograft composed of the amnion and chorion layer of the placental membrane.